Daiichi Sankyo and AstraZeneca’s Datroway Approved in EU for Breast Cancer
Japan-based Daiichi Sankyo (TYO: 4568) and UK major AstraZeneca (NASDAQ: AZN) announced that their co-developed...
April 2025
IDT and Shanghai Bioscience Forge Partnership to Drive Local Innovation in China
Integrated DNA Technologies (IDT), a leading life sciences and diagnostics company under the Danaher Corporation...
Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...
Winsunny Pharma’s FY101 Gains NMPA Clinical Approval for Hyperlipidemia
China-based Beijing Winsunny Pharmaceutical Co., Ltd (SHA: 601089) announced that it has received clinical approval...
HighLife SAS’s TMVR System Receives FDA Breakthrough Device Designation
Medical device firm HighLife SAS, the French partner of China-based Peijia Medical Limited (HKG: 9996),...
Zhifei Biological Gains Bangladesh Approval for Dysentery Vaccine Trial
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has received clearance from the Directorate General...
Hengrui Pharmaceuticals’ Vunakizumab Approved for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
CSPC Pharmaceutical’s JMT108 Gains FDA Approval for Advanced Malignant Tumor Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...
Amgen’s Uplizna Approved by FDA for IgG4-Related Disease
US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China
China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...
J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...
Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation
Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...
AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...
SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...
Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau
China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...
Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation
China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...
Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...
Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors
China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...
Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency
The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...